Boussen et al. [39] initially enrolled IBC patients with HER2-positive and HER2-negative disease; however, HER2-negative patients were excluded from the analysis because of lack of efficacy of lapatinib and slow accrual. Here, ERBB2 is linked to inflammatory breast carcinoma.